Jump to content

Recipra

From Medico-Pharmaceutical Law Universe (by Lumen SI)
Revision as of 00:52, 12 November 2026 by Valentin (talk | contribs) (Add complete multilingual reference and language navigation)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Recipra

Recipra is presented as a conceptual proposal from the development of Vision 2035 Revision 2027. Valentyn Shapovalov's article Recipra as a Proposed Successor to Ethics (An Advance Contribution from Vision 2035 Revision 2027) was published on 4 October 2026 in Conceptual Future, 1(1), 27–34.

The proposal emphasizes reciprocal accountability: the ability of a less powerful party to obtain justification, challenge a decision and secure correction without first matching the authority's resources. It discusses duties concerning evidence, access, review, remedy and freedom of association.

Status: proposed framework and research agenda. The article acknowledges an unresolved difficulty when a powerful actor can refuse every review mechanism. This page does not present Recipra as an established universal replacement for ethics or a validated intervention.

Source